edward b. garon, md, on the implications of keynote-189
Published 5 years ago • 66 plays • Length 2:11
Download video MP4
Download video MP3
Similar videos
-
2:37
edward b. garon, md, considers the implications of keynote-001 in advanced nsclc
-
1:46
edward b. garon, md, elaborates on the role of pd-l1 in the management of lung cancer
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
0:59
martin e. gutierrez, md, regarding the implications of the initial & updated results of keynote 189
-
6:16
keynote-189: clinical implications in patients with low (1-49%) tumor pd-l1 expression (bmic-032)
-
7:58
keynote-189: clinical implications for high tumor pd-l1 expression (bmic-031)
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
5:33
significance of keynote-189 in nsclc
-
11:43
dr. klotman's video message - week 229
-
27:08
immunotherapy advances in small cell lung cancer
-
4:48
keynote-091 and impower010: adjuvant chemotherapy for nsclc
-
1:06
benjamin philip levy, md, discusses the practice-changing outcomes from keynote 189
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
1:01
dr. garon on the keynote-001 study in nsclc
-
1:18
ravi salgia, md, phd, on the ideal patient to receive alimta plus keytruda based on keynote-189
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:57
keynote 189: targeting nsclc patients with brain and liver metastases
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
2:39
edward garon md, expounds on the new fda approval of erlotinib ramuciramab in egfr positive ansclc
-
1:30
david r. gandara, md, on whether keynote 189 impacted view of pdl-1 expression and patient selection
Clip.africa.com - Privacy-policy